Efficacy and Safety of Mazdutide in Chinese Participants with Overweight or Obesity


In a recent announcement, Innovent Biologics, a renowned biopharmaceutical company, shared the positive results of their clinical study on mazdutide at the American Diabetes Association’s (ADA) 84th Scientific Sessions. Mazdutide, a GLP-1R/GCGR dual agonist, is a promising treatment option for individuals with overweight or obesity.

The company presented the findings of their Phase 3 study, GLORY-1, which focused on Chinese adults with obesity and overweight. The study showcased the efficacy and safety of mazdutide in reducing weight and improving metabolic indicators. Moreover, an exploratory analysis of GLORY-1 revealed an improvement in liver steatosis among the participants.

Dr. Linong Ji from Peking University People’s Hospital presented the oral presentation on GLORY-1’s findings, highlighting the significance of mazdutide as the first GLP-1R/GCGR dual agonist to successfully complete a Phase 3 registration study for overweight/obesity. Additionally, two posters were presented on the Phase 2 study of mazdutide 9 mg in Chinese adults with moderate-to-severe obesity, further demonstrating the potential benefits of this innovative treatment.

Mazdutide, also known as IBI362, is an oxyntomodulin (OXM) analogue that exhibits GLP-1 receptor agonist effects. Clinical studies have shown that mazdutide effectively promotes weight loss, lowers blood glucose levels, and improves various cardio-metabolic indicators. It has demonstrated positive outcomes such as reducing waist circumference, blood lipids, blood pressure, liver enzymes, and liver fat content, as well as enhancing insulin sensitivity.

Innovent, in collaboration with Eli Lilly and Company, has been actively developing mazdutide for potential commercialization in China. The company is conducting multiple Phase 3 studies, including GLORY-1 and GLORY-2 for overweight or obese individuals and DREAMS-1, DREAMS-2, and DREAMS-3 for those with type 2 diabetes. GLORY-1 and DREAMS-2 have already met their primary endpoints.

These successful study results have paved the way for Innovent to submit the first New Drug Application (NDA) for mazdutide to the China National Medical Products Administration (NMPA) for chronic weight management in adults with obesity or overweight.

Innovent, committed to providing high-quality and affordable biologics, continues to contribute to the advancement of the biopharmaceutical industry. With ongoing collaborations with global healthcare leaders and an extensive pipeline of innovative therapies, Innovent strives to make first-rate pharmaceutical drugs accessible to all individuals in need.

Disclaimer: This article is for informational purposes only and does not constitute medical advice.

Additional Facts:

1. Current Market Trends: The market for anti-obesity drugs is growing steadily, driven by the increasing prevalence of overweight and obesity globally. The demand for effective and safe treatments for weight management is high, as individuals seek solutions to improve their health and well-being.

2. Forecasts: The global anti-obesity drug market is expected to reach a value of $6.3 billion by 2027, with a compound annual growth rate (CAGR) of 25.9% from 2020 to 2027. This growth can be attributed to factors such as increasing awareness about the health risks associated with obesity, rising healthcare expenditure, and advancements in drug development.

3. Key Challenges or Controversies: The efficacy and safety of anti-obesity drugs have been subject to debate and scrutiny. Some drugs have faced concerns regarding their potential side effects, such as cardiovascular risks, gastrointestinal issues, or psychiatric disorders. It is crucial for researchers and healthcare professionals to thoroughly evaluate the benefits and risks of new treatments to ensure patient safety.

Pressing Questions:

1. What are the potential advantages of mazdutide as a treatment for overweight or obesity?
– Mazdutide, as a GLP-1R/GCGR dual agonist, offers a unique mechanism of action that can target multiple pathways involved in weight regulation. This dual action can potentially lead to enhanced weight loss and metabolic improvements compared to single-target drugs.

2. Are there any disadvantages or limitations associated with the use of mazdutide?
– While mazdutide shows promise, its long-term safety and efficacy still need further evaluation. Additionally, the availability and affordability of the drug, once approved, could be a challenge for widespread access.

Advantages of Mazdutide:
– Mazdutide has demonstrated positive outcomes in terms of weight loss, blood glucose control, and improvements in cardio-metabolic indicators.
– Clinical studies have shown reductions in waist circumference, blood lipids, blood pressure, liver enzymes, and liver fat content, as well as improvements in insulin sensitivity.

Disadvantages of Mazdutide:
– The long-term safety and efficacy of mazdutide require further investigation.
– The accessibility and affordability of the drug, once approved, may pose challenges for certain populations.

Suggested Related Links:
Innovent Biologics
Eli Lilly and Company
China National Medical Products Administration